Lipocine (NASDAQ:LPCN) Announces Earnings Results

Lipocine (NASDAQ:LPCN) posted its earnings results on Thursday. The specialty pharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.31, Zacks reports. The firm had revenue of $2.29 million during the quarter, compared to analyst estimates of $0.16 million. Lipocine had a negative net margin of 755.39% and a negative return on equity of 64.75%.

Lipocine Price Performance

Shares of NASDAQ LPCN traded up $0.04 during midday trading on Friday, reaching $1.57. 507,960 shares of the company traded hands, compared to its average volume of 702,409. Lipocine has a 52 week low of $1.36 and a 52 week high of $12.37. The stock has a 50-day moving average price of $1.93 and a 200 day moving average price of $3.81. The company has a market cap of $12.94 million, a price-to-earnings ratio of -0.88 and a beta of 0.49.

Analysts Set New Price Targets

Several equities research analysts have commented on LPCN shares. Weiss Ratings upgraded shares of Lipocine from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, October 29th. HC Wainwright reaffirmed a “neutral” rating and set a $4.00 price target on shares of Lipocine in a report on Monday, September 21st. Wall Street Zen upgraded Lipocine from a “sell” rating to a “hold” rating in a research report on Saturday, July 18th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Lipocine in a report on Tuesday, September 22nd. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Lipocine presently has an average rating of “Hold” and an average price target of $4.00.

Insiders Place Their Bets

In related news, Director John Higuchi acquired 15,970 shares of Lipocine stock in a transaction that occurred on Wednesday, September 30th. The stock was acquired at an average price of $2.23 per share, with a total value of $35,613.10. Following the completion of the acquisition, the director directly owned 241,365 shares of the company’s stock, valued at $538,243.95. This trade represents a 7.09% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have bought a total of 37,568 shares of company stock valued at $82,174 over the last three months. Corporate insiders own 4.69% of the company’s stock.

About Lipocine

Lipocine Inc is a biopharmaceutical company focused on developing oral therapies for conditions with significant unmet medical needs. The company uses its proprietary Lip’ral drug-delivery technology to improve the absorption and clinical performance of active pharmaceutical ingredients that may otherwise have limited effectiveness when taken orally.

Lipocine’s lead product is Tlando, an oral testosterone replacement therapy containing testosterone undecanoate. The U.S. Food and Drug Administration approved Tlando in 2022 for testosterone replacement therapy in adult males with hypogonadism associated with an underlying medical condition.